Minimal Residual Disease Assessment in Multiple Myeloma: Utility and Feasibility in Resource Constraint Settings of India

Hematological Oncology - United Kingdom
doi 10.1002/hon.2439_150
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley

Related search

Minimal Residual Disease Assessment in the Context of Multiple Myeloma Treatment

Current Hematologic Malignancy Reports
Cancer ResearchOncologyHematology
2016English

The Utility of Non-Invasive Liquid Biopsy for Mutational Analysis and Minimal Residual Disease Assessment in Extramedullary Multiple Myeloma

British Journal of Haematology
Hematology
2020English

Flow Cytometry in the Diagnosis and Monitoring of Minimal Residual Disease in Multiple Myeloma

Oncogematologiya
OncologyHematology
2017English

Minimal Residual Disease Testing After Stem Cell Transplantation for Multiple Myeloma

Bone Marrow Transplantation
TransplantationHematology
2015English

Association of Minimal Residual Disease With Superior Survival Outcomes in Patients With Multiple Myeloma

JAMA Oncology
Cancer ResearchOncology
2017English

Serological Normalisation as a Surrogate Marker for Minimal Residual Disease Negativity in Multiple Myeloma

British Journal of Haematology
Hematology
2018English

Is This the Time to Introduce Minimal Residual Disease in Multiple Myeloma Clinical Practice?

Clinical Cancer Research
Cancer ResearchOncology
2015English

A CD138-independent Strategy to Detect Minimal Residual Disease and Circulating Tumour Cells in Multiple Myeloma

British Journal of Haematology
Hematology
2016English

Prospective Trial of Minimal Residual Disease Assessment by Multiparametric Flow Cytometry for Multiple Myeloma in the Era of Bortezomib-Based Chemotherapy

Biology of Blood and Marrow Transplantation
TransplantationHematology
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy